Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...

DUBLIN--(BUSINESS WIRE)--The "Global Mobile Satellite Services (MSS) Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global Mobile ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) ...

Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers 28-Jun-2024 / 10:39 GMT/BST ...

Adagene will present updated clinical data for ADG126 at a prominent oncology symposium, indicating progress in their research and development efforts. The presentation includes new data on a higher ...

Study shows botensilimab “switches on” the body’s own T-cells to attack a common, treatment-resistant form of colorectal cancer Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented ...

These results are particularly meaningful, as the landscape of MSS colorectal cancer treatment has seen little advancement leaving a significant gap in effective therapies for patients. “MSS ...